CLINICAL TRIALS PROFILE FOR EPINASTINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for EPINASTINE HYDROCHLORIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00407927 ↗ | A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2006-12-01 | The purpose of this trial is to determine the safety, efficacy and tolerability of two doses of the study drug compared to placebo for the treatment of subjects with seasonal allergic rhinitis. |
NCT00489398 ↗ | Comparison of CL Wear Between Two Allergy Drops | Withdrawn | Merck Sharp & Dohme Corp. | Phase 4 | 2007-07-01 | Comparison of two allergy drops for enhancing comfort and performance of contact lens wear |
NCT00489398 ↗ | Comparison of CL Wear Between Two Allergy Drops | Withdrawn | Hom, Milton M., OD, FAAO | Phase 4 | 2007-07-01 | Comparison of two allergy drops for enhancing comfort and performance of contact lens wear |
NCT00564421 ↗ | Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-12-18 | The purpose of this study is to determine the safety and efficacy of epinastine nasal spray compared to placebo for the treatment of subjects with seasonal allergic rhinitis |
NCT01382654 ↗ | Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2006-09-01 | The objectives of this study were to: - Examine the tolerability of two formulations and two dose concentrations of epinastine. - Select formulation(s) of epinastine for future studies by evaluating the individual sensory attribute scores of the Nasal Spray Evaluation Questionnaire (NSEQ) collected after each study drug administration and the subject preference ranking assessed at the completion of the study. - Compare the preference of two formulations and two dose concentrations of epinastine compared to azelastine following a single dose of each in a randomized, double-blind, two-cohort, three-period crossover design. |
NCT01569191 ↗ | Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis | Completed | University of Worcester | Phase 4 | 2012-03-01 | Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever. Treatments that can be used before initiating medical therapy include artificial tear supplements (ATS) and cold compresses (CC). However, there is no evidence in the scientific literature that demonstrates their efficacy compared to no treatment or their combined effect with anti-allergic medication. Therefore the investigators aim to examine the efficacy of ATS and CC alone, in comparison to anti-allergic medication, and CC in combination with anti-allergic medication. In addition, the investigators also aim to determine the time course of ocular allergic reactions. At the end of the study the investigators will be able to see whether or not ATS and CC are effective in treating SAC. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EPINASTINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for EPINASTINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for EPINASTINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for EPINASTINE HYDROCHLORIDE
Sponsor Name